Mersana Therapeutics Inc (MRSN) Stock
MRSN is no longer traded. Mersana Therapeutics was delisted from the Nasdaq in January 2026.
Prices on this page are historical; the last trade was January 2, 2026 at $29.04.
Mersana Therapeutics stock price history
MRSN final trading statistics
- Final close
- $29.04
- Final trading day
- Jan 2, 2026
- Market cap at delisting
- $145.16M
- Shares outstanding
- 5.00M
- Final 52-week range
- $0.26 – $29.39
- Avg. volume (final 3 mo.)
- 125,752
- All-time high (split-adj.)
- $689.75 · Dec 2020
- All-time low (split-adj.)
- $5.97 · Aug 2025
- Return since IPO
- -91.7%
- Beta
- 0.43
- Book value / share
- -$11.91
- Price / book
- -2.44
Mersana Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $40.50M | -$69.2M | -$0.56 |
| FY2023 | $36.85M | -$171.7M | -$1.42 |
| FY2022 | $26.58M | -$204.2M | -$2.19 |
| FY2021 | $43.0K | -$170.1M | -$2.40 |
| FY2020 | $828.0K | -$88.0M | -$1.43 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Mersana Therapeutics Inc
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. As of January 6, 2026, Mersana Therapeutics, Inc. operates as a subsidiary of Day One Biopharmaceuticals, Inc.
Mersana Therapeutics stock FAQ
What happened to Mersana Therapeutics stock?
Mersana Therapeutics stock was delisted from the Nasdaq. Its final close was $29.04 on January 2, 2026.
Is MRSN stock still trading?
No. MRSN was delisted from the Nasdaq in January 2026 and no longer trades on a U.S. exchange.
What was the last price of MRSN stock?
MRSN closed at $29.04 on its final trading day, January 2, 2026, for a market value of about $145.16M.
What were Mersana Therapeutics's revenue and earnings in its last full fiscal year?
Mersana Therapeutics reported revenue of $40.50M and net income of -$69.2M in fiscal 2024, its last full year as a public company.
When did Mersana Therapeutics go public?
Mersana Therapeutics Inc stock began trading on June 28, 2017.